Solid Bioscience News Today

Solid Biosciences Inc. (NASDAQ:SLDB – Free Report) – Analysts at HC Wainwright reduced their Q2 2024 EPS estimates for Solid Biosciences in a research note issued to investors on Monday, May 20th. HC Wainwright analyst A. He now anticipates that the company will post earnings per share of ($0.72) for the quarter, down from their […]

Immunovant (NASDAQ:IMVT – Get Free Report) and Solid Biosciences (NASDAQ:SLDB – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, profitability, risk, dividends, earnings and analyst recommendations. Analyst Ratings This is a summary of current ratings […]

Solid Biosciences Inc. (NASDAQ: SLDB) shares traded higher on Thursday. The company announced that it received Fast Track Designation from the U.S.

Solid Biosciences Inc. (NASDAQ:SLDB – Free Report) – Stock analysts at Leerink Partnrs boosted their Q3 2023 earnings per share (EPS) estimates for shares of Solid Biosciences in a report released on Wednesday, August 16th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($1.05) for the quarter, […]

Solid Biosciences Inc. (NASDAQ:SLDB – Free Report) – Equities research analysts at Leerink Partnrs raised their Q3 2023 earnings per share (EPS) estimates for Solid Biosciences in a research note issued to investors on Wednesday, August 16th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($1.05) per share for […]

Arcellx (NASDAQ:ACLX – Get Rating) and Solid Biosciences (NASDAQ:SLDB – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk and institutional ownership. Risk and Volatility Arcellx has a beta of -0.33, indicating […]

DBV Technologies (NASDAQ:DBVT – Get Rating) and Solid Biosciences (NASDAQ:SLDB – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, analyst recommendations and profitability. Profitability This table compares DBV Technologies and Solid Biosciences’ […]

DBV Technologies (NASDAQ:DBVT – Get Rating) and Solid Biosciences (NASDAQ:SLDB – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability. Risk and Volatility DBV Technologies has a beta of […]

Research collaboration to target severe form of genetic dilated cardiomyopathyCollaboration strengthens Solid Biosciences’ scientific capabilities and commercial potential in cardiac... | January 11, 2023

Equities analysts predict that Solid Biosciences Inc. (NASDAQ:SLDB – Get Rating) will report earnings of ($0.21) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Solid Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.23) and the highest estimate coming in at ($0.17). Solid Biosciences […]